Citations

Showing 10 of 108083 citations.

Response by Brinjikji to Letter Regarding Article “Neurons Over Nephrons: Systematic Review and Meta-Analysis of Contrast-Induced Nephropathy in Patients With Acute Stroke”
Brinjikji, Waleed

Mayo Clinic

Stroke | September 2, 2017 | Volume: 48 | Issue: 10 | Pages: No page available

10.1161/strokeaha.117.018960 | PMID 28864599 Get It

Patterns of necrosis in liver disease
Krishna, Murli

Mayo Clinic

Clinical Liver Disease | September 1, 2017 | Volume: 10 | Issue: 2 | Pages: 53-56

10.1002/cld.653 | PMID 30992760 Get It

Pathology and differential diagnosis of hepatic venous outflow impairment
Nakhleh, Raouf E.

Mayo Clinic

Clinical Liver Disease | September 1, 2017 | Volume: 10 | Issue: 2 | Pages: 49-52

10.1002/cld.647 | PMID 30992759 Get It

Critical Care Organizations: Business of Critical Care and Value/Performance Building*
Leung, Sharon, Gregg, Sara, Oropello, John M., Brown, Daniel R. , Kvetan, Vladimír, Coopersmith, Craig M , Layon, Abraham Joseph , Pastores, Stephen M.

Mayo Clinic

Critical Care Medicine | September 1, 2017 | Volume: 46 | Issue: 1 | Pages: 1-11

10.1097/ccm.0000000000002696 | PMID 28863012 Get It

Objective: New, value-based regulations and reimbursement structures are creating historic care management challenges, thinning the margins and threatening the viability of hospitals and health systems. The Society of Critical Care Medicine convened a taskforce of Academic Leaders in Critical Care Medicine on February 22, 2016, during the 45th Critical Care Congress to develop a toolkit drawing on the experience of successful leaders of critical care organizations in North America for advancing critical care organizations (Appendix 1). The goal of this article was to provide a roadmap and call attention to key factors that adult critical care medicine leadership in both academic and nonacademic setting should consider when planning for value-based care. Design: Relevant medical literature was accessed through a literature search. Material published by federal health agencies and other specialty organizations was also reviewed. Collaboratively and iteratively, taskforce members corresponded by electronic mail and held monthly conference calls to finalize this report. Setting: The business and value/performance critical care organization building section comprised of leaders of critical care organizations with expertise in critical care administration, healthcare management, and clinical practice. Measurements and Main Results: Two phases of critical care organizations care integration are described: “horizontal,” within the system and regionalization of care as an initial phase, and “vertical,” with a post-ICU and postacute care continuum as a succeeding phase. The tools required for the clinical and financial transformation are provided, including the essential prerequisites of forming a critical care organization; the manner in which a critical care organization can help manage transformational domains is considered. Lastly, how to achieve organizational health system support for critical care organization implementation is discussed. Conclusions: A critical care organization that incorporates functional clinical horizontal and vertical integration for ICU patients and survivors, aligns strategy and operations with those of the parent health system, and encompasses knowledge on finance and risk will be better positioned to succeed in the value-based world.
Sex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation
Shantha, Ghanshyam Palamaner Subash , Inampudi, Chakradhari , Kumar, Anita , Chaikriangkrai, Kongkiat , Bhise, Viraj , Deshmukh, Abhishek , Patel, Nileshkumar , Horwitz, Phillip A. , Mickelsen, Steven , Bhave, Prashant D. , Oral, Hakan , Vaughan‐Sarrazin, Mary , Mentias, Amgad , Pancholy, Samir , GIUDICI, MICHAEL C. , Vaughan Sarrazin, Mary

Mayo Clinic

Journal of the American Heart Association | September 1, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.117.006381 | PMID 28862952 Get It

Background Sex‐specific effectiveness of rivaroxaban ( RIVA ), dabigatran ( DABI ), and warfarin in reducing myocardial infarction ( MI ), heart failure ( HF ), and all‐cause mortality among patients with atrial fibrillation are not known. We assessed sex‐specific associations of RIVA , DABI , or warfarin use with the risk of MI , HF , and all‐cause mortality among patients with atrial fibrillation. Methods and Results Medicare beneficiaries (men: 65 734 [44.8%], women: 81 135 [55.2%]) with atrial fibrillation who initiated oral anticoagulants formed the study cohort. Inpatient admissions for MI , HF , and all‐cause mortality were compared between the 3 drugs separately for men and women using 3‐way propensity‐matched samples. In men, RIVA use was associated with a reduced risk of MI admissions compared with warfarin use (hazard ratio [95% confidence interval ( CI ): 0.59 [0.38–0.91]), with a trend towards reduced risk compared with DABI use (0.67 [0.44–1.01]). In women, there were no significant differences in the risk of MI admissions across all 3 anticoagulants. In both sexes, RIVA use and DABI use were associated with reduced risk of HF admissions (men: RIVA ; 0.75 [0.63–0.89], DABI ; 0.81 [0.69–0.96]) (women: RIVA ; 0.64 [0.56–0.74], DABI ; 0.73 [0.63–0.83]) and all‐cause mortality (men: RIVA ; 0.66 [0.53–0.81], DABI ; 0.75 [0.61–0.93]) (women: RIVA ; 0.76 [0.63–0.91], DABI ; 0.77 [0.64–0.93]) compared with warfarin use. Conclusions RIVA use and DABI use when compared with warfarin use was associated with a reduced risk of HF admissions and all‐cause mortality in both sexes. However, reduced risk of MI admissions noted with RIVA use appears to be limited to men.
Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
Salim, Kowthar Y., Vareki, Saman Maleki , San‐Marina, Serban , Koropatnick, James , San-Marina, Serban, Danter, Wayne R.

Mayo Clinic

Oncotarget | September 1, 2017 | Volume: 8 | Issue: 36 | Pages: 60724-60724

10.18632/oncotarget.20600 | PMID 29062467 Get It

Olaratumab for the treatment of advanced soft tissue sarcoma
Okuno, Scott H. , Maran, Avudaiappan , Robinson, Steven I.

Mayo Clinic

Expert Review of Anticancer Therapy | September 1, 2017 | Volume: 17 | Issue: 10 | Pages: 883-887

10.1080/14737140.2017.1374857 | PMID 28862476 Get It

Patient‐ and Cell Type‐Specific Heterogeneity of Metformin Response
Barron, Matthew, Aubry, Marie Christine, Wigle, Dennis A. , Asiedu, Michael K.

Mayo Clinic

Basic & Clinical Pharmacology & Toxicology | September 1, 2017 | Volume: 122 | Issue: 2 | Pages: 214-222

10.1111/bcpt.12898 | PMID 28862803 Get It

AbstractMost FDA‐approved drugs are not equally effective in all patients, suggesting that identification of biomarkers to predict responders to a chemoprevention agent will be needed to stratify patients and achieve maximum benefit. The goal of this study was to investigate both patient‐specific and cell context‐specific heterogeneity of metformin response, using fibroblast cell lines and induced pluripotent stem cells differentiated into lung epithelial lineages. We performed cell survival analysis, transcriptome and whole exome sequencing analysis on both patient‐derived cell lines and cancer cell lines to assess differential metformin response and identify response genes. We found differences in response to metformin treatment across a variety of cell lines and cellular contexts, suggesting that heterogeneity may be patient‐ and cell type‐specific. Gene expression profiling and analysis of metformin‐sensitive and metformin‐resistant cells identified differentially expressed genes that may be able to stratify patients into metformin responders and non‐responders. Sequencing analysis found genomic alterations that correlated with metformin response. These results suggest that the identification of genomic biomarkers for patients who may respond to metformin treatment can provide an opportunity for individualizing metformin chemoprevention in the clinical setting.
A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions
Ando, Tomo , Takagi, Hisato , Briasoulis, Αlexandros , Telila, Tesfaye , Slovut, David P., Afonso, Luis , Schreiber, Theodore , Briasoulis, Alexandros, Briasoulis, Alexandros , Grines, Cindy L.

Mayo Clinic

Catheterization and Cardiovascular Interventions | September 1, 2017 | Volume: 91 | Issue: 1 | Pages: 124-134

10.1002/ccd.27256 | PMID 28862381 Get It

AbstractObjectivesTo summarize the published data of combined transcatheter aortic and mitral valve intervention (CTAMVI).BackgroundCTAMVI, a combination of either transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve‐in‐valve (TAViV) and transcatheter mitral valve replacement (TMVR), transcatheter mitral valve‐in‐valve/valve‐in‐ring (TMViV/ViR), or percutaneous mitral valve repair (PMVR) is an attractive alternative in high‐surgical risk patients with combined aortic and mitral valve disease. However, its procedural details and clinical outcomes have not been well described.MethodsWe performed a systematic review of all the published articles from PUBMED and EMBASE.ResultsA total of 37 studies with 60 patients were included. The indication for CTAMVI was high or inoperable surgical risk and symptomatic severe aortic stenosis (92%) or severe aortic regurgitation (8%) combined with moderate to severe/severe mitral stenosis (30%) or moderate/severe mitral regurgitation (65%) or both (5%). In majority of the cases, aortic valve intervention was performed prior to the mitral valve. Mortality rate were 25% for TAVR + TMVR (range 42 days to 10 months), 17% for TAVR + TMViV/ViR (range 13 days to 6 months), 0% for TAViV + TMViV/ViR (range 6–365 days), and 15% for TAVR/ViV + PMVR (range 17 days to 419 days). Significant (more than moderate) paravalvular regurgitation post‐procedure was rare.ConclusionsCTAMVI appears to confer reasonable clinical outcome. Further large study is warranted to clarify the optimal strategy, procedural details and clinical outcomes in the future.
Satori: Awakening to Outcomes That Matter: The Impact of Social Support in Chronic Obstructive Pulmonary Disease
Benzo, Roberto

Mayo Clinic

Annals of the American Thoracic Society | September 1, 2017 | Volume: 14 | Issue: 9 | Pages: 1385-1386

10.1513/annalsats.201707-526ed | PMID 28862500 Get It